Are the estrogen receptors involved in Alzheimer's disease?

J. C. Lambert, J. M. Harris, H.a. Lemmon, A. Cummings, J. Coates, D. Mann, David Malcolm St Clair

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Retrospective analysis shows that women who took estrogen replacement therapy may have less risk of cognitive decline and of developing Alzheimer's disease (AD). The greater risk associated with female gender and these observations suggest that estrogen may be implicated in the aetiology of AD. Estrogen is one of a family of sex steroids that exerts many of its genomic effects through the activation of the nuclear estrogen receptors, ER alpha and ER beta. Previously, increased risk for AD has been reported for polymorphisms in the ER alpha gene in a Japanese cohort, however, this association has not been systematically replicated. We have further investigated polymorphisms in the ER alpha and have extended this to investigate an association with a polymorphism within the ER beta gene in an independent UK Caucasian population. We found no independent association of these polymorphisms with the risk of developing AD in the total sample nor within either gender. However, we did detect a significant interaction between the ER alpha and ER beta polymorphisms and the risk for AD (OR = 0.22 95% CI (0.05-0.88), P = 0.02). If this finding can be supported in other independent studies, it may suggest that the risk for AD may be modulated only when both ER alpha and ER beta have particular variations in their expression and/or biological activities. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)193-197
Number of pages4
JournalNeuroscience Letters
Volume306
Issue number3
Early online date8 Jun 2001
DOIs
Publication statusPublished - 29 Jun 2001

Keywords

  • Alzheimer's disease
  • estrogen receptor
  • polymorphisms
  • Alpha gene polymorphisms
  • association
  • risk
  • age
  • increases
  • women
  • APOE

Cite this

Lambert, J. C., Harris, J. M., Lemmon, H. A., Cummings, A., Coates, J., Mann, D., & St Clair, D. M. (2001). Are the estrogen receptors involved in Alzheimer's disease? Neuroscience Letters, 306(3), 193-197. https://doi.org/10.1016/S0304-3940(01)01806-7

Are the estrogen receptors involved in Alzheimer's disease? / Lambert, J. C.; Harris, J. M.; Lemmon, H.a.; Cummings, A.; Coates, J.; Mann, D.; St Clair, David Malcolm.

In: Neuroscience Letters, Vol. 306, No. 3, 29.06.2001, p. 193-197.

Research output: Contribution to journalArticle

Lambert, JC, Harris, JM, Lemmon, HA, Cummings, A, Coates, J, Mann, D & St Clair, DM 2001, 'Are the estrogen receptors involved in Alzheimer's disease?', Neuroscience Letters, vol. 306, no. 3, pp. 193-197. https://doi.org/10.1016/S0304-3940(01)01806-7
Lambert JC, Harris JM, Lemmon HA, Cummings A, Coates J, Mann D et al. Are the estrogen receptors involved in Alzheimer's disease? Neuroscience Letters. 2001 Jun 29;306(3):193-197. https://doi.org/10.1016/S0304-3940(01)01806-7
Lambert, J. C. ; Harris, J. M. ; Lemmon, H.a. ; Cummings, A. ; Coates, J. ; Mann, D. ; St Clair, David Malcolm. / Are the estrogen receptors involved in Alzheimer's disease?. In: Neuroscience Letters. 2001 ; Vol. 306, No. 3. pp. 193-197.
@article{8805dc18a6f644ea8b8b264ef57e9fd6,
title = "Are the estrogen receptors involved in Alzheimer's disease?",
abstract = "Retrospective analysis shows that women who took estrogen replacement therapy may have less risk of cognitive decline and of developing Alzheimer's disease (AD). The greater risk associated with female gender and these observations suggest that estrogen may be implicated in the aetiology of AD. Estrogen is one of a family of sex steroids that exerts many of its genomic effects through the activation of the nuclear estrogen receptors, ER alpha and ER beta. Previously, increased risk for AD has been reported for polymorphisms in the ER alpha gene in a Japanese cohort, however, this association has not been systematically replicated. We have further investigated polymorphisms in the ER alpha and have extended this to investigate an association with a polymorphism within the ER beta gene in an independent UK Caucasian population. We found no independent association of these polymorphisms with the risk of developing AD in the total sample nor within either gender. However, we did detect a significant interaction between the ER alpha and ER beta polymorphisms and the risk for AD (OR = 0.22 95{\%} CI (0.05-0.88), P = 0.02). If this finding can be supported in other independent studies, it may suggest that the risk for AD may be modulated only when both ER alpha and ER beta have particular variations in their expression and/or biological activities. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.",
keywords = "Alzheimer's disease, estrogen receptor, polymorphisms, Alpha gene polymorphisms, association, risk, age, increases, women, APOE",
author = "Lambert, {J. C.} and Harris, {J. M.} and H.a. Lemmon and A. Cummings and J. Coates and D. Mann and {St Clair}, {David Malcolm}",
year = "2001",
month = "6",
day = "29",
doi = "10.1016/S0304-3940(01)01806-7",
language = "English",
volume = "306",
pages = "193--197",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Are the estrogen receptors involved in Alzheimer's disease?

AU - Lambert, J. C.

AU - Harris, J. M.

AU - Lemmon, H.a.

AU - Cummings, A.

AU - Coates, J.

AU - Mann, D.

AU - St Clair, David Malcolm

PY - 2001/6/29

Y1 - 2001/6/29

N2 - Retrospective analysis shows that women who took estrogen replacement therapy may have less risk of cognitive decline and of developing Alzheimer's disease (AD). The greater risk associated with female gender and these observations suggest that estrogen may be implicated in the aetiology of AD. Estrogen is one of a family of sex steroids that exerts many of its genomic effects through the activation of the nuclear estrogen receptors, ER alpha and ER beta. Previously, increased risk for AD has been reported for polymorphisms in the ER alpha gene in a Japanese cohort, however, this association has not been systematically replicated. We have further investigated polymorphisms in the ER alpha and have extended this to investigate an association with a polymorphism within the ER beta gene in an independent UK Caucasian population. We found no independent association of these polymorphisms with the risk of developing AD in the total sample nor within either gender. However, we did detect a significant interaction between the ER alpha and ER beta polymorphisms and the risk for AD (OR = 0.22 95% CI (0.05-0.88), P = 0.02). If this finding can be supported in other independent studies, it may suggest that the risk for AD may be modulated only when both ER alpha and ER beta have particular variations in their expression and/or biological activities. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.

AB - Retrospective analysis shows that women who took estrogen replacement therapy may have less risk of cognitive decline and of developing Alzheimer's disease (AD). The greater risk associated with female gender and these observations suggest that estrogen may be implicated in the aetiology of AD. Estrogen is one of a family of sex steroids that exerts many of its genomic effects through the activation of the nuclear estrogen receptors, ER alpha and ER beta. Previously, increased risk for AD has been reported for polymorphisms in the ER alpha gene in a Japanese cohort, however, this association has not been systematically replicated. We have further investigated polymorphisms in the ER alpha and have extended this to investigate an association with a polymorphism within the ER beta gene in an independent UK Caucasian population. We found no independent association of these polymorphisms with the risk of developing AD in the total sample nor within either gender. However, we did detect a significant interaction between the ER alpha and ER beta polymorphisms and the risk for AD (OR = 0.22 95% CI (0.05-0.88), P = 0.02). If this finding can be supported in other independent studies, it may suggest that the risk for AD may be modulated only when both ER alpha and ER beta have particular variations in their expression and/or biological activities. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.

KW - Alzheimer's disease

KW - estrogen receptor

KW - polymorphisms

KW - Alpha gene polymorphisms

KW - association

KW - risk

KW - age

KW - increases

KW - women

KW - APOE

U2 - 10.1016/S0304-3940(01)01806-7

DO - 10.1016/S0304-3940(01)01806-7

M3 - Article

VL - 306

SP - 193

EP - 197

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 3

ER -